ABSTRACT 111 In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient in the detection of insulinomas. We aimed at determining whether novel PET/CT imaging with [Nle 14 ,Lys 40 (Ahx-DOTA-68 Ga)NH 2 ]exendin-4 ( 68 Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign insulinomas.
INTRODUCTION
The most common cause of endogenous hyperinsulinemic hypoglycemia in adults is an insulinoma. Endogenous hyperinsulinemic hypoglycemia is biochemically diagnosed by a prolonged supervised fasting test in an inpatient setting (1) . Approximately 5-10% of insulinomas are multiple, mainly in the context of multiple endocrine neoplasia type 1, less than 10% are malignant, and the majority are benign single insulinomas (1) . The only curative treatment of an insulinoma is its surgical removal. Therefore the exact preoperative localization of the insulinoma is critical in order to plan the surgical intervention (1) . Magnetic resonance imaging (MRI), computed tomography (CT) or endoscopic ultrasound are normally used to localize insulinomas (1) . However the small size (often <1 cm), limits the sensitivity of these methods (1) . The sensitivity can be increased by including methods such as angiography with selective arterial calcium stimulation and hepatic venous sampling. However, this procedure is invasive with concomitant risks for complications. The sensitivity of somatostatin receptor scintigraphy and SPECT/CT is usually low (33-50%) and inconsistent for 18 F-DOPA PET (90% in a prospective study and 20% in a retrospective study) (2 
MATERIALS AND METHODS

Patients
Five consecutive patients were screened and accepted for our prospective pilot study. Patients were referred from four tertiary centers in Switzerland. All patients fulfilled the following inclusion criteria: biochemically proven endogenous hyperinsulinemic hypoglycemia with neuroglycopenic symptoms, negative screening for sulfonylurea (exclusion of hypoglycemia factitia), contrast enhanced 3T MRI not older than 2 months and age above 18 years. Patients with evidence of malignant insulinoma in conventional imaging were excluded, as well as pregnant women, patients with allergies to exendin-4, and patients with renal insufficiency (blood creatinine concentrations >140 μmol/L).
The institutional review board approved this study and all subjects signed a written informed consent.
Procedures
111 In-DOTA-exendin-4 SPECT/CT and 68 Ga-DOTA-exendin-4 PET/CT were performed within 24-73 hours in randomized cross-over order. Synthesis and labelling of 68 Ga-DOTA-exendin-4 and 111 In-DOTA-exendin-4 were described elsewhere (7) . All patients received unenhanced low-dose CT for attenuation correction and anatomical reference (120 kVp, 30-100 mAs). Blood samples were taken 2, 5, 15, 30, 60, 120 and 180 min after injection of 68 Ga-DOTA-exendin-4 and 111 In-DOTA-exendin-4 to measure blood glucose levels and blood clearance. An additional blood sample was taken 300 min after injection of 111 In-DOTA-exendin-4. All conventional scans were independently reported by experienced radiologists at the referral centers. GLP-1R SPECT/CT and PET/CT scans were independently assessed by 2 board-certified nuclear medicine physicians. Both readers were blinded to other imaging results and the patient's clinical history. In case of discordant finding, a consensus between the two nuclear medicine physicians was found. Tumor-to-background ratios were measured for 111 In-DOTA-exendin-4 (counts) and 68 Ga-DOTA-exendin-4 (maximal standardized uptake values).
Histological diagnosis was regarded as the standard for comparison. The pathologists were blinded to the results of other diagnostic tests but were aware of the patient's clinical history.
Finally, GLP-1R expression was evaluated in vitro by GLP-1R autoradiography as previously described (8) .
by
RESULTS
The clinical characteristics are summarized in Table 1 . In all five patients a fasting test was performed. Symptoms of neuroglycopenia in association with low plasma glucose levels (mean 2.1, range 1.6-2.6 mmol/L) and inadequately increased insulin (mean 12.1, range 3.9-21.9 mU/L) and C-peptide (mean 0.714, range 0.5-0.98 nmol/L) levels was documented in all patients after 12-52 h of fasting.
The labeling yield of 111 In-and 68 Ga-DOTA-exendin-4 was >95% and the radiochemical purity was ≥95% for 111 In-DOTA-exendin-4 and ≥93% for 68 Ga-DOTA-exendin-4, at a specific activity of Imaging results are summarized in Table 2 . In patient 4 focal uptake of 111 In-DOTA-exendin-4 and 68 Ga-DOTA-exendin-4 was highly suspicious for an insulinoma (Figure 1 ), however the patient has refused surgery so far.
All patients received exogenous glucose infusion (1000 mL, 10%) just before injection of the radiotracer for 5 hours. In doing so, no severe hypoglycemic episodes occurred. Two patients experienced nausea and two patients experienced nausea and vomiting after injection of 111 In-DOTA-exendin-4. One patient experienced nausea after the injection of 68 Ga-DOTA-exendin-4.
No other adverse effects were observed.
In all four operated patients histology confirmed the diagnosis of a benign insulin producing tumor ( Table 2 ) and symptoms of hypoglycemia resolved immediately after surgery.
Histopathological diagnosis was made at the local institution. In patient 5 imaging and additional in vitro GLP-1R autoradiography was performed (Figure 2 and 3) . Late 111 In-DOTA-exendin-4 SPECT scans (72 hours p.i.) showed a slightly higher tumor-tobackground ratio than early SPECT scan. This is consistent with our previously published work (2) in which we suggested late scans 3-7 days after injection in patients with negative early scans. However, late scans may increase the risk for false positive results. This can be explained by the physiological expression of GLP-1R in pancreatic islets/acini and Brunner's gland of the duodenum (8).
The faster imaging procedure, higher tumor-to-background ratio, better spatial resolution (5) and lower radiation burden of 68 Ga-DOTA-exendin-4 PET/CT (7) favors this novel method over 111 In-DOTA-exendin-4 SPECT/CT. Furthermore, absolute quantification of tumor and background uptake, which might be useful to improve interobserver agreement and specificity, is better This study has limitations. First, conventional imaging could not be standardized because of differences in local availability. However, MRI was performed in all patients. Second, conventional imaging had the tendency to underperform compared with published literature (1, 10) . This might be explained by the fact that most patients were referred following negative conventional imaging and are therefore part of a negative selection. Finally only 5 patients have been investigated. However, this study was planned as a pilot study. Due to the promising results a larger study evaluating GLP-1R PET/CT is initiated.
CONCLUSION
This study proofs that 68 Ga-DOTA-exendin-4 PET/CT is feasible and a sensitive tool for the detection of insulinomas. The higher spatial resolution, the possibility of quantification and lower radiation burden favors 68 Ga-DOTA-exendin-4 PET/CT over 111 In-DOTA-exendin-4 SPECT/CT. 
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